Venetoclax Combined with Pediatric-Inspired Chemotherapy Enhances Outcomes in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia
Highlight
This prospective phase 2 study reveals that integrating the BCL-2 inhibitor venetoclax into pediatric-inspired chemotherapy in adolescents and adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) considerably improves measurable residual disease (MRD) negativity rates and promotes superior survival outcomes compared to historical controls, without adding significant toxicity.
Key findings include a high complete remission (CR) rate of 91.0%, MRD negativity achieved in 73.0% of responders after induction, and estimated 2-year overall survival and disease-free survival rates exceeding 75%.
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.